BRIEF published on 11/14/2025 at 23:10, 7 months 11 days ago MaaT Pharma : levée de fonds réussie de 9,1 millions d'euros Biotechnologie Innovation Médicale Investisseurs Microbiome Levée De Fonds
BRIEF published on 11/14/2025 at 23:10, 7 months 11 days ago MaaT Pharma: successful fundraising of 9.1 million euros Investors Biotechnology Fundraising Microbiome Medical Innovation
PRESS RELEASE published on 11/14/2025 at 23:05, 7 months 11 days ago Inside Information / Operations of the issuer (acquisitions, sales...) MaaT Pharma successfully completes Global Offering of €9.1 million, strengthening financial position and supporting development of Microbiome Therapies for cancer patients Financial Position Global Offering MaaT Pharma Cancer Patients Microbiome Therapies
PRESS RELEASE published on 11/14/2025 at 23:05, 7 months 11 days ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) MaaT Pharma annonce le succès de son Offre Globale de 9,1 millions d'euros pour le développement de Microbiome Ecosystem Therapies™. Levée de fonds pour Xervyteg® et MaaT033 Microbiome Ecosystem Therapies Offre Globale MaaT Pharma MaaT033 Xervyteg
BRIEF published on 11/13/2025 at 19:45, 7 months 12 days ago MaaT Pharma launches a capital increase Capital Increase Qualified Investors MaaT Pharma Global Offer Xervyteg® Marketing
BRIEF published on 11/13/2025 at 19:45, 7 months 12 days ago Lancement d'une augmentation de capital par MaaT Pharma Augmentation De Capital Investisseurs Qualifiés Offre Globale MaaT Pharma Xervyteg® Commercialisation
PRESS RELEASE published on 11/13/2025 at 19:40, 7 months 12 days ago Informations privilégiées / Autres communiqués MaaT Pharma lance une augmentation de capital de 9 millions d'euros pour financer son développement. Offre d'actions nouvelles aux investisseurs. Projets de développement clinique et commercialisation Développement Augmentation De Capital Commercialisation Actions Nouvelles MaaT Pharma
PRESS RELEASE published on 11/13/2025 at 19:40, 7 months 12 days ago Inside Information / Other news releases MaaT Pharma launches a capital increase of approximately €9 million through a private placement and PrimaryBid offering. Funds raised to support Xervyteg® commercialization and extend cash runway until summer 2026 Private Placement Investment Capital Increase MaaT Pharma Xervyteg
BRIEF published on 11/05/2025 at 07:35, 7 months 21 days ago MaaT Pharma dévoile des données précliniques prometteuses pour MaaT034 Immunothérapie Traitement Du Cancer MaaT Pharma Thérapie Du Microbiome MaaT034
Published on 06/26/2026 at 01:40, 6 hours 58 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 9 hours 8 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 10 hours 8 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 11 hours 6 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 17 hours 8 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 08:00, 38 minutes ago MHM Corporate: Debt Restructuring through Bonds Redeemable in Shares
Published on 06/26/2026 at 08:00, 38 minutes ago MHM Corporate: Restructuration de sa dette par voie d'obligations remboursables en actions
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago REINET INVESTMENTS S.C.A. ANNOUNCES REVISED DATE FOR ANNUAL GENERAL MEETING
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago THE NAGA GROUP AG CONFIRMS FY 2025 REVENUES AND REPORTS STRONGER-THAN-EXPECTED EBITDA
Published on 06/26/2026 at 07:30, 1 hour 8 minutes ago Pyrum Innovations AG reports results for the first three months of 2026
Published on 06/26/2026 at 07:00, 1 hour 38 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 1 hour 38 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 13 hours 53 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 14 hours 8 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 14 hours 48 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
